---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-035865"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:34:07.404439+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock reports FY2023 net loss of $165.8M; cash $280M; SAPPHIRE data expected 4Q 2024

## Summary
- Net loss $165.8M ($1.99/share) vs $134.5M ($2.26/share) in FY2022; no revenue vs $33.2M prior year.
- R&D spend $121.9M, G&A $49.4M; cash $280M expected to fund operations into 2H 2025.
- Phase 3 SAPPHIRE trial (apitegromab in SMA) topline data on track for 4Q 2024; potential launch 2025 if approved.
- FDA cleared IND for Phase 2 obesity trial of apitegromab + GLP-1 RA; start mid-2024, data mid-2025.
- Appointed Katie Peng to board; promoted Mo Qatanani to CSO in Feb 2024.

## SEC filing metadata
- accession: 0001104659-24-035865
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/0001104659-24-035865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/tm249126d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-035865
- JSON: https://secwatch.observer/filing/0001104659-24-035865.json
- Plain text: https://secwatch.observer/filing/0001104659-24-035865.txt

## Key facts
- Earnings Releases
  Scholar Rock Holding Corp reported the full year ended December 31, 2023 results: net income $165.8 million or $1.99 per share, EPS $1.99 per share.
  - Period: the full year ended December 31, 2023
  - Net income: $165.8 million or $1.99 per share
  - EPS: $1.99 per share
  - Result: reported results
  source text: Full Year 2023 Financial Results For the full year ended December 31, 2023, net loss was $165.8 million or $1.99 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1727196/000110465924035865/0001104659-24-035865-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.